{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:19:00Z","timestamp":1773832740238,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cellimm.2023.104675","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:40:01Z","timestamp":1675042801000},"page":"104675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice"],"prefix":"10.1016","volume":"385","author":[{"given":"Thais B.","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-998X","authenticated-orcid":false,"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep R.P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreevani","family":"Arisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cox","family":"Terhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Daniell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moanaro","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2023.104675_b0005","doi-asserted-by":"crossref","unstructured":"A. Iorio, J.S. Stonebraker, H. Chambost, M. Makris, D. Coffin, C. Herr, F. Germini, Data, H. Demographics Committee of the World Federation of, Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries, Ann. Intern. Med., 171 (2019) 540-546.","DOI":"10.7326\/M19-1208"},{"key":"10.1016\/j.cellimm.2023.104675_b0010","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3389\/fimmu.2017.01604","article-title":"Innovative approaches for immune tolerance to factor VIII in the treatment of Hemophilia A","volume":"8","author":"Sherman","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2023.104675_b0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/TCRM.S4412","article-title":"Recombinant factor VIII in the management of hemophilia A: current use and future promise","volume":"5","author":"Powell","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.cellimm.2023.104675_b0020","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.cellimm.2023.104675_b0025","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of Hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2023.104675_b0030","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016530","article-title":"Immune complications and their management in inherited and acquired bleeding disorders","author":"Arruda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2006.06359.x","article-title":"Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors","volume":"136","author":"Reipert","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2023.104675_b0045","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"International Immune Tolerance, The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0050","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cellimm.2023.104675_b0055","doi-asserted-by":"crossref","unstructured":"H.M. van den Berg, K. Fischer, M. Carcao, H. Chambost, G. Kenet, K. Kurnik, C. Konigs, C. Male, E. Santagostino, R. Ljung, G. PedNet Study, Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A, Blood, 134 (2019) 317-320.","DOI":"10.1182\/blood.2019000658"},{"key":"10.1016\/j.cellimm.2023.104675_b0060","doi-asserted-by":"crossref","unstructured":"S.C. Gouw, H.M. van den Berg, K. Fischer, G. Auerswald, M. Carcao, E. Chalmers, H. Chambost, K. Kurnik, R. Liesner, P. Petrini, H. Platokouki, C. Altisent, J. Oldenburg, B. Nolan, R.P. Garrido, M.E. Mancuso, A. Rafowicz, M. Williams, N. Clausen, R.A. Middelburg, R. Ljung, J.G. van der Bom, PedNet, I.d.S.G. Research of Determinants of, Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study, Blood, 121 (2013) 4046-4055.","DOI":"10.1182\/blood-2012-09-457036"},{"issue":"Suppl 1","key":"10.1016\/j.cellimm.2023.104675_b0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1538-7836.2009.03417.x","article-title":"Role of regulatory T cells in tolerance to coagulation factors","volume":"7","author":"Cao","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cellimm.2023.104675_b0070","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0075","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2019.00274","article-title":"Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice","volume":"10","author":"Herzog","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.30","article-title":"Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia","volume":"1","author":"Sarkar","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.cellimm.2023.104675_b0085","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.ymthe.2021.04.034","article-title":"CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII","volume":"29","author":"Rana","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.cellimm.2023.104675_b0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","article-title":"In vivo induction of regulatory T cells for immune tolerance in hemophilia","volume":"301","author":"Wang","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0100","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2014-09-599266","article-title":"Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg","volume":"125","author":"Biswas","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0105","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cellimm.2023.104675_b0110","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/mt.2011.61","article-title":"In vivo expansion of regulatory T cells with IL-2\/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy","volume":"19","author":"Liu","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.cellimm.2023.104675_b0115","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/00007890-199912150-00005","article-title":"Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection","volume":"68","author":"Friend","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.cellimm.2023.104675_b0120","first-page":"603","volume":"381","author":"Herold","year":"2019","journal-title":"Type 1 Diabetes TrialNet Study"},{"key":"10.1016\/j.cellimm.2023.104675_b0125","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2023.104675_b0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cellimm.2023.104675_b0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1900\/RDS.2012.9.372","article-title":"CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic","volume":"9","author":"Chatenoud","year":"2012","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.cellimm.2023.104675_b0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI16090","article-title":"Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)","volume":"111","author":"Herold","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cellimm.2023.104675_b0145","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.4049\/jimmunol.165.11.6205","article-title":"Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells","volume":"165","author":"Carpenter","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0150","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.1100713","article-title":"Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells","volume":"187","author":"Penaranda","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0155","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1084\/jem.20100205","article-title":"Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints","volume":"207","author":"Nishio","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.cellimm.2023.104675_b0160","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm1408","article-title":"Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells","volume":"12","author":"Ochi","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cellimm.2023.104675_b0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clim.2017.07.005","article-title":"Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice","volume":"183","author":"Ogura","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0170","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/db06-1632","article-title":"Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody","volume":"56","author":"Ishikawa","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.cellimm.2023.104675_b0175","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/425021","article-title":"Induction of immunological tolerance by oral anti-CD3","volume":"2012","author":"da Cunha","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0180","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.109.863431","article-title":"Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice","volume":"120","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cellimm.2023.104675_b0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cei.13159","article-title":"Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH","volume":"193","author":"Ilan","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0190","doi-asserted-by":"crossref","unstructured":"G. Lalazar, M. Mizrahi, I. Turgeman, T. Adar, A. Ben Ya'acov, Y. Shabat, A. Nimer, N. Hemed, L. Zolotarovya, Y. Lichtenstein, N. Lisovoder, S. Samira, I. Shalit, R. Ellis, Y. Ilan, Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial, J Clin Immunol, 35 (2015) 399-407.","DOI":"10.1007\/s10875-015-0160-6"},{"key":"10.1016\/j.cellimm.2023.104675_b0195","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1053\/j.gastro.2012.07.019","article-title":"An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice","volume":"143","author":"Forster","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2023.104675_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1359-6101(99)00010-6","article-title":"Latent transforming growth factor-beta binding proteins (LTBPs)\u2013structural extracellular matrix proteins for targeting TGF-beta action","volume":"10","author":"Saharinen","year":"1999","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cellimm.2023.104675_b0205","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-143259","article-title":"Revisiting the \u201cDanger Theory\u201d: Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8\u03b1+ and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation","volume":"136","author":"Kaczmarek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0210","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/bloodadvances.2019000650","article-title":"Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice","volume":"3","author":"Jing","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.cellimm.2023.104675_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880829","article-title":"Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway","volume":"13","author":"Patel","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaut.2016.10.001","article-title":"Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain","volume":"76","author":"Kuhn","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cellimm.2023.104675_b0225","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood-2009-05-217315","article-title":"Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy","volume":"114","author":"Peng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0230","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/mt.2009.159","article-title":"Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B","volume":"17","author":"Cao","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.cellimm.2023.104675_b0235","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cellimm.2023.104675_b0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cellimm.2023.104675_b0245","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"Siner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/intimm\/dxu083","article-title":"In vivo anti-LAP mAb enhances IL-17\/IFN-gamma responses and abrogates anti-CD3-induced oral tolerance","volume":"27","author":"da Cunha","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0255","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","article-title":"CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice","volume":"158","author":"Chatenoud","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0260","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20052016","article-title":"Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells","volume":"203","author":"Worbs","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.cellimm.2023.104675_b0265","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0270","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood-2013-10-528737","article-title":"Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells","volume":"124","author":"Sherman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0275","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/pbi.12859","article-title":"Expression and assembly of largest foreign protein in chloroplasts: oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in haemophilia A mice","volume":"16","author":"Kwon","year":"2018","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.cellimm.2023.104675_b0280","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.pcl.2015.07.013","article-title":"Mechanisms of Oral Tolerance","volume":"62","author":"Commins","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.cellimm.2023.104675_b0285","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","article-title":"Antigen-specific immunotherapy of autoimmune and allergic diseases","volume":"22","author":"Sabatos-Peyton","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cellimm.2023.104675_b0290","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1073\/pnas.0908771107","article-title":"Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice","volume":"107","author":"Ilan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cellimm.2023.104675_b0295","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jvh.12369","article-title":"Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial","volume":"22","author":"Halota","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cellimm.2023.104675_b0300","first-page":"1895","article-title":"Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis, Endocr Metab Immune Disord Drug","volume":"21","author":"Nourelden","year":"2021","journal-title":"Targets"},{"key":"10.1016\/j.cellimm.2023.104675_b0305","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1073\/pnas.93.1.388","article-title":"Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells","volume":"93","author":"Chen","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cellimm.2023.104675_b0310","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/(SICI)1097-4547(19990215)55:4<432::AID-JNR4>3.0.CO;2-2","article-title":"Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11","volume":"55","author":"Bebo","year":"1999","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.cellimm.2023.104675_b0315","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00125-018-4593-3","article-title":"Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice","volume":"61","author":"Chen","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cellimm.2023.104675_b0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.imlet.2019.08.008","article-title":"Oral delivery of single-chain insulin (SCI-59) analog by bacterium-like particles (BLPs) induces oral tolerance and prevents autoimmune diabetes in NOD mice","volume":"214","author":"Mao","year":"2019","journal-title":"Immunol Lett"},{"key":"10.1016\/j.cellimm.2023.104675_b0325","first-page":"400","article-title":"Type 1 diabetes mellitus and its oral tolerance therapy, World","volume":"11","author":"Mao","year":"2020","journal-title":"J Diabetes"},{"key":"10.1016\/j.cellimm.2023.104675_b0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/s10165-009-0210-0","article-title":"Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis","volume":"19","author":"Park","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cellimm.2023.104675_b0335","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cellimm.2023.104675_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.06.012","article-title":"Plant cell-made protein antigens for induction of Oral tolerance","volume":"37","author":"Daniell","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.cellimm.2023.104675_b0345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biomaterials.2015.08.004","article-title":"Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B","volume":"70","author":"Su","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.cellimm.2023.104675_b0350","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","article-title":"Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce","volume":"25","author":"Herzog","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2023.104675_b0355","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.0912181107","article-title":"Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice","volume":"107","author":"Verma","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2023.104675_b0360","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/mt.2016.115","article-title":"Oral delivery of protein drugs bioencapsulated in plant cells","volume":"24","author":"Kwon","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2023.104675_b0365","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fimmu.2020.00844","article-title":"Role of small intestine and gut microbiome in plant-based oral tolerance for Hemophilia","volume":"11","author":"Kumar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2023.104675_b0370","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/blood-2014-08-597070","article-title":"Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0375","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104675_b0380","doi-asserted-by":"crossref","unstructured":"E.K. Boden, J.B. Canavan, C.J. Moran, K. McCann, W.A. Dunn, F.A. Farraye, A.N. Ananthakrishnan, V. Yajnik, R. Gandhi, D.D. Nguyen, A.K. Bhan, H.L. Weiner, J.R. Korzenik, S.B. Snapper, Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis, Crohns Colitis 360, 1 (2019) otz009.","DOI":"10.1093\/crocol\/otz009"},{"key":"10.1016\/j.cellimm.2023.104675_b0385","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41419-018-0927-9","article-title":"CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production","volume":"9","author":"Yu","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cellimm.2023.104675_b0390","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20081811","article-title":"CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance","volume":"206","author":"Friedline","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2023.104675_b0395","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.4049\/jimmunol.1602031","article-title":"Relationship between CD4 Regulatory T cells and anergy in vivo","volume":"198","author":"Kalekar","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2023.104675_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cellimm.2023.104675_b0405","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1467-7652.2007.00259.x","article-title":"Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts\u2013oral administration protects against development of insulitis in non-obese diabetic mice","volume":"5","author":"Ruhlman","year":"2007","journal-title":"Plant Biotechnol. J."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887492300014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887492300014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:10:06Z","timestamp":1757805006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000887492300014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":81,"alternative-id":["S000887492300014X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104675","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104675"}}